Pfizer Seeks To Block Infringement Of Sutent Patent In India
Pfizer is pushing ahead with legal action in India to ward off an alleged infringer of its patent on Sutent - a product that has had a checkered patent journey in the country.
You may also be interested in...
Two patent revocations later, Pfizer has received a significant reprieve with India's Intellectual Property Appellate Board (IPAB) sending the case concerning its anticancer, Sutent (sunitinib malate), back to the Controller General of Patents to review the matter afresh.
Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.
Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.